Ascendis Pharma Endocrinology Division A/S: Financial statements 2016
CVR: 32323537
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
Ascendis Pharma Endocrinology Division A/S (CVR 32323537) has filed annual accounts for 2016. In 2016, the company reported a gross profit of EUR -42,307,040 and a net result of EUR -44,006,494 compared with EUR -29,557,717 the year before. Equity in the 2016 report amounted to EUR -88,262,489.
- Gross Profit
- EUR -42,307,040
- Profit/Loss
- EUR -44,006,494
- Equity
- EUR -88,262,489
- Total Assets
- EUR 3,665,310
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | -42.3M EUR | -44M EUR | -88.3M EUR | - |
| 2015 | - | -28.8M EUR | -29.6M EUR | -44.3M EUR | - |
| 2014 | - | -11.2M EUR | -11.5M EUR | -14.7M EUR | - |
| 2013 | - | -46.2M | -47.3M | -36.9M | - |
Official annual report
Find more companies like Ascendis Pharma Endocrinology Division A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
Ascendis Pharma Endocrinology Division A/S has published its annual report for 2015. Gross profit came to DKK -28,800,471, and the net result was DKK -29,557,717.
On March 14, 2016, the company changed its name from ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S to Ascendis Pharma Endocrinology Division A/S.
About Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, GROWTH DISORDERS DIVISION A/S and ACP 30.06.2012 2 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported revenue of EUR 140,817,000 and a net result of EUR -38,806,000 compared with EUR -121,118,000 the year before. Equity in the 2025 report amounted to EUR -935,650,000.
